AlphaTON Capital Corp (NASDAQ: ATON), the world’s leading public technology company developing the super app Telegram, with an addressable market of 1 billion monthly active users, today announced plans to launch a decentralized, native AI biotechnology platform focused on rare and immunocompromised cancers, starting with mesothelioma.
The planned platform is designed as a decentralized, privacy-focused AI network for rare cancers that can learn across institutions without centralizing sensitive patient data. In its initial phase, AlphaTON expects the platform to provide near-term practical outcomes for mesothelioma, including biomarker and responder insights, enrichment strategies and trial design simulations to help inform upcoming mesothelioma clinical trials at Cyncado Therapeutics, a wholly owned subsidiary of AlphaTON, as well as prioritization of repurposed candidates and new combinations. Over time, the platform is intended to evolve into a continuous therapeutic discovery and development engine, progressing toward the design of new drugs.
The platform will initially be trained on proprietary oncology datasets and learnings from AlphaTON subsidiary Cyncado Therapeutics’ program, providing a solid foundation and a significant head start in the development of rare cancer models. AlphaTON then plans to expand the training base with additional proprietary datasets from partners, subject to appropriate permissions and governance.
The initiative will be advanced through a dedicated platform entity that will seek independent third-party funding and non-dilutive funding at the platform level, while AlphaTON’s role will focus on infrastructure provision, governance and strategic alignment.
This initiative is intended to be a flagship, real-world application of AlphaTON’s broader Cocoon AI strategy, leveraging the company’s recently announced GPU deployments and increasing high-performance computing capacity to support privacy-focused decentralized AI.
The platform is designed to bring together:
- Privacy-focused multi-institutional learning so that models learn at hospitals and sponsors while sensitive data stays where it is
- A therapy discovery engine to classify reuse opportunities, prioritize new combinations, and generate testable hypotheses for new drug design over time
- Stakeholder intelligence to surface biomarkers, guide enrichment, and support potential companion diagnostic pathways
- Rare Cancer Trial Manuals suitable for low patient volume settings, including parameters, design scenarios and protocol optimization
- Large-scale infrastructure using Telegram distribution, TON rails for credentials, consent and contribution, and Cocoon compute, including the recently announced B200 and H200 GPU deployments and expansion of data center capacity to support demanding oncology AI workloads and rapid iterations
Participation in multi-institutional collaborations should be subject to institutional approvals, patient consent where appropriate, and compliance with applicable privacy and data protection laws.
Native Telegram Engagement and Contributor Recognition
AlphaTON plans to build a Telegram-native scientific collaboration layer designed to accelerate engagement and learning in the field of rare cancers. This may include non-transferable TON-based contribution credentials, such as badges, to recognize verified scientific contributions, including curation and annotation of datasets, model validation, protocol simulation, biomarker review, and hypothesis generation.
Relationship with Cyncado Therapeutics
Cyncado Therapeutics is a wholly owned subsidiary of AlphaTON and owns TT-4, TT-10 and associated intellectual property and datasets generated under its programs. AlphaTON anticipates that the platform entity will enter into a multi-year data and R&D agreement with Cyncado to license and curate relevant datasets and support translational and correlative work related to AI-generated hypotheses. Cyncado is expected to remain the IND holder and clinical sponsor of its programs.
Next steps in the short term
Over the next approximately 12 months, AlphaTON plans to establish the entity and governance of the dedicated platform, finalize initial data and R&D agreements, and launch an initial version of the platform anchored on Cyncado datasets as well as select external cohorts. The Company expects this first phase to produce concrete near-term results for mesothelioma, including prioritized reuse and combination hypotheses, early insights into biomarkers and enrichment, and trial design simulations to inform future clinical plans. In parallel, AlphaTON plans to initiate one to two multi-institutional pilot collaborations and launch Telegram’s native scientific collaboration layer, including contribution credentials and targeted workflows to accelerate curation, annotation, and validation of dataset models.
As the platform matures, AlphaTON plans to evaluate a structured approach to advancing individual assets, including the ability to license or acquire rights to promising therapies in dedicated SPVs with program-specific funding to support targeted clinical trials under clear governance and set-aside budgets, while also using insights generated by the platform to inform new drug design over time.
Brittany Kaiser, Managing Director of AlphaTON Capital, said: “Rare cancers have world-class science, but the data is scattered and patient numbers are low. We believe decentralized privacy-focused AI can help institutions and sponsors learn faster together, without consolidating sensitive patient data in one place.
Peter Molloy, President and CEO of Cyncado Therapeutics, said: “Cyncado brings proprietary data sets and program learnings in mesothelioma and other hard-to-treat settings that can launch this platform from day one. Our intention is to maintain Cyncado as an IND-holding clean biotech while enabling a privacy-focused network to translate multi-institutional learning into practical therapeutic advances, from repurposing to combinations, and eventually new drug design.
This press release is provided for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities.
About AlphaTON Capital Corp. (Nasdaq: ATON)
AlphaTON Capital Corp (NASDAQ: ATON) is the world’s first public technology company developing the Telegram super app, with an addressable market of 1 billion monthly active users while managing a strategic reserve of digital assets. The Company implements a comprehensive M&A and treasury strategy that combines direct token acquisition, validation operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram’s billion-user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company. Led by Chief Executive Officer Brittany Kaiser, Executive Chairman and Chief Investment Officer Enzo Villani, and Chief Business Development Officer Yury Mitin, the Company’s activities span network validation and staking operations, Telegram-based application development, and strategic investments in TON-based decentralized financial protocols, gaming platforms, and commercial applications.
AlphaTON Capital Corp is a company incorporated in the British Virgin Islands and traded on Nasdaq under the symbol “ATON”. AlphaTON Capital, through its legacy businesses, is also advancing first-in-class therapies targeting known checkpoint resistance pathways to achieve durable therapeutic responses and improve patient quality of life. AlphaTON Capital actively engages in the drug development process and provides strategic advice to guide the development of new immunotherapy assets and combinations of assets. To learn more, please visit https://alphatoncapital.com/.
Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the future financial performance of AlphaTON and involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the development and adoption of AI technologies, cryptocurrency market volatility, regulatory developments, technical challenges related to infrastructure deployment and general economic conditions. AlphaTON undertakes no obligation to update any forward-looking statements, except as required by law.
Investor relations:
AlphaTON Capital Corp.
(email protected)
(203) 682-8200
Media inquiries:
Richard Laermer
RP RLM
(email protected)
(212) 741-5106 ext. 216
